---
title: ACS
author: J. Austin Straley, DO
date: 2022-11-24
categories:
    - Cardiology
tags:
    - Chest Pain
    - ACS
---
## Background

- Completely or partially occluding thrombus on a disrupted atherothrombotic coronary plaque leading to myocardial ischemia
- STEMI: Elevated troponin & elevation in ST segment or new LBBB with
    symptoms
    - \> 0.1 mV in at least 2 contiguous leads
    - Exception, in V2-V3:
        - \> 0.2 mV in men older than 40 y/o
        - \> 0.25 in men younger than 40 y/o
        - \> 0.15 mV in women
- NSTEMI: Evidence of myocardial necrosis (elevated troponin) w/o ST
    segment elevation
- Unstable Angina: Angina without evidence of myocardial necrosis
    (normal troponin + normal EKG)

### Acute Myocardial Infarction

- [Definition][3]
    - The term **acute myocardial infarction** should be used when there is acute myocardial injury with clinical evidence of acute myocardial ischemia + detection of a rise and/or fall of cTn values with at least one value above the 99th percentile URL + least one of the following:
        - Symptoms of myocardial ischemia
        - New ischemic ECG changes
        - Development of pathological Q waves
        - Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality in a pattern consistent with an ischemic etiology
        - Identification of a coronary thrombus by angiography or autopsy (not for type 2 or 3 MIs)
    - Post-mortem demonstration of acute atherothrombosis in the artery supplying the infarcted myocardium meets criteria for type 1 MI
    - Evidence of an imbalance between myocardial oxygen supply and demand unrelated to acute atherothrombosis meets criteria for type 2 MI
    - Cardiac death in patients with symptoms suggestive of myocardial ischemia and presumed new ischemia ECG changes before cTn values become available or abnormal meets criteria for type 3 MI

## Management

- P2Y12
    - [PLATO][1]: Ticagrelor > Clopidogrel in ACS including mortality
    - [DAPT][2]: Continuing Thienopyridine after 12 months decreased risk of In-stent thrombosis and MI at 18 months, increased risk of bleeding
    - [WOEST][4]: Bleeding w/AC + Plavix < Triple Therapy w/o change in MI/Stroke/MACE
    - [COGENT][5]: PPI with DAPT reduces GIB 87%, no CV event change
- Statins
    - [PROVE-IT][6]: Significantly reduced CVD events following MI with High-dose Lipitor vs. Pravastatin
- ACEI
    - [SAVE][7]: ACEI improve survival/morbidity/mortality in LV dysfunction after MI
- [MADIT-II][8]: ICD improves survival in pts with prior MI and severe LV dysfunction

## Other Resources

- [PowerPoint: ACS Survival Guide - Seaberg CAMC/WVU 2022](https://www.dropbox.com/scl/fi/cd76rcwo7wxofonpiyth4/Cards-ACS-Survival-Guide-Seaberg-2022.pptx?rlkey=1n9dbr552d9rh0nxy3flvgcfv&dl=0)

[1]: http://www.ncbi.nlm.nih.gov/pubmed/19717846
[2]: https://pubmed.ncbi.nlm.nih.gov/25399658/{:target="_blank"}
[3]: https://pubmed.ncbi.nlm.nih.gov/30153967/{:target="_blank"}
[4]: https://pubmed.ncbi.nlm.nih.gov/23415013/{:target="_blank"}
[5]: https://pubmed.ncbi.nlm.nih.gov/20925534/{:target="_blank"}
[6]: http://www.ncbi.nlm.nih.gov/pubmed/15007110
[7]: https://pubmed.ncbi.nlm.nih.gov/1386652/{:target="_blank"}
[8]: https://pubmed.ncbi.nlm.nih.gov/11907286/{:target="_blank"}
